A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome

Prenatal Diagnosis

Volumn 35, Issue 5, 2015, Pages 440-446

  Walker, Brandon S ^a   Jackson, Brian R ^a   Lagrave, Danielle ^a   Ashwood, Edward R ^a   Schmidt, Robert L ^a  

^a ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CELL FREE DNA; UNCLASSIFIED DRUG; DNA;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA SCREENING; DOWN SYNDROME; FEMALE; HEALTH CARE COST; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; MORBIDITY; MORTALITY; PREGNANT WOMAN; PRIORITY JOURNAL; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; INDUCED ABORTION; PREGNANCY; PRENATAL DIAGNOSIS;

ABORTION, INDUCED; COST-BENEFIT ANALYSIS; DNA; DOWN SYNDROME; FEMALE; HUMANS; MONTE CARLO METHOD; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84928383536     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4511     Document Type: Article

References (59)

1. Ashoor G, Syngelaki A, Wagner M, et al. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206(4):322 e1-5.
2. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119(5):890-901.
3. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342c7401.
4. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204(3):205 e1-11.
5. Nicolaides KH, Syngelaki A, Ashoor G, et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207(5):374 e1-6.
6. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207(2):137 e1-8.
7. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13(11):913-20.
8. Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206(4):319.e1-e9.
9. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012;32(13):1233-41.
10. Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn 2006;26(9):769-77.
11. Palomaki GE, Knight GJ, Ashwood ER, et al. Screening for down syndrome in the United States: results of surveys in 2011 and 2012. Arch Pathol Lab Med 2013;137(7):921-6.
12. Committee opinion no. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120(6):1532-4.
13. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013;33(7):622-9.
14. Devers PL, Cronister A, Ormond KE, et al. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns 2013;22(3):291-5.
15. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15(5):395-8.
16. Wilson KL, Czerwinski JL, Hoskovec JM, et al. NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. J Genet Couns 2013;22(1):4-15.
17. Agarwal A, Sayres LC, Cho MK, et al. Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn 2013;33(6):521-31.
18. Non-invasive prenatal testing (NIPT). this is my: Health Screening & Ultrasound Centres [cited 2014 April 3]. Available from: http://www.thisismy.co.uk/non-invasive-prenatal-testing-nipt/.
19. Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis. Prenat Diagn 2013;33(7):636-42.
20. Garfield SS, Armstrong SO. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Manage Care Med 2012;15(2):32-9.
21. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med 2013;26(12):1180-5.
22. Morris S, Karlsen S, Chung N, et al. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service. PLoS One 2014;9(4):e93559.
23. Waitzman NJ, Scheffler RM, Romano PS. The Cost of Birth Defects: Estimates of the Value of Prevention. Lanham, MD: University Press of America, 1996.
24. Gold M, Siegel J, Russell L, et al. Cost-Effectiveness in Health and Medicine. USA: Oxford University Press, 1996 July 18, 1996.
25. Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd edn), New York: Oxford University Press, Incorporated; 2005 July 21, 2005.
26. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10(2):56-104.
27. Wald N, Rodeck C, Rudnicka A, et al. Nuchal translucency and gestational age. Prenat Diagn 2004;24(2):150-1.
28. Wald N, Leck I. Antenatal and Neonatal Screening (2nd edn), USA: Oxford University Press, 2000 December 15.
29. Stata Statistical Software: Release 12. College Station, TX, USA: StataCorp, 2011.
30. Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19(2):142-5.
31. Centers for Disease Control and Prevention. National Center for Health Statistics: VitalStats; 2009 [cited 2012]. Available from: http://www.cdc.gov/nchs/vitalstats.htm.
32. TreeAge Pro 2012. TreeAge Software Inc, Williamstown, Massachusetts, USA, 2012.
33. CMS.gov. Centers for Medicare & Medicaid Services. Available from: http://www.cms.gov.
34. Jones RK, Kooistra K. Abortion incidence and access to services in the United States, 2008. Perspect Sex Reprod Health 2011;43(1):41-50.
35. Kucik JE, Shin M, Siffel C, et al. Trends in survival among children with Down syndrome in 10 regions of the United States. Pediatrics 2013;131(1):e27-36.
36. Day SM, Strauss DJ, Shavelle RM, et al. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol. 2005;47(3):171-6.
37. Personal consumption expenditures index: Bureau of Ecomonic Analysis; [cited 2014 April 15]. Available from: http://www.bea.gov/.
38. Employment Cost Index: Bureau of Labor Statistics; [cited 2014 April 15]. Available from: http://www.bls.gov.
39. Rowe R, Puddicombe D, Hockley C, et al. Offer and uptake of prenatal screening for Down syndrome in women from different social and ethnic backgrounds. Prenat Diagn 2008;28(13):1245-50.
40. Weisz B, Pandya P, Chitty L, et al. Practical issues drawn from the implementation of the integrated test for Down syndrome screening into routine clinical practice. BJOG 2007;114(4):493-7.
41. Tischler R, Hudgins L, Blumenfeld YJ, et al. Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenat Diagn 2011;31(13):1292-9.
42. Lewis C, Hill M, Silcock C, et al. Non-invasive prenatal testing for trisomy 21: a cross-sectional survey of service users' views and likely uptake. BJOG, 2014;121(5):582-94.
43. Lewis C, Silcock C, Chitty LS. Non-invasive prenatal testing for Down's syndrome: pregnant women's views and likely uptake. Public Health Genomics 2013;16(5):223-32.
44. Baker D, Teklehaimanot S, Hassan R, et al. A look at a Hispanic and African American population in an urban prenatal diagnostic center: referral reasons, amniocentesis acceptance, and abnormalities detected. Genet Med 2004;6(4):211-8.
45. Jaques AM, Collins VR, Muggli EE, et al. Uptake of prenatal diagnostic testing and the effectiveness of prenatal screening for Down syndrome. Prenat Diagn 2010;30(6):522-30.
46. Mueller VM, Huang T, Summers AM, et al. The influence of risk estimates obtained from maternal serum screening on amniocentesis rates. Prenat Diagn 2005;25(13):1253-7.
47. Spencer K, Spencer CE, Power M, et al. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003;110(3):281-6.
48. Bishop J, Huether CA, Torfs C, et al. Epidemiologic study of Down syndrome in a racially diverse California population, 1989-1991. Am J Epidemiol 1997;145(2):134-47.
49. Forrester MB, Merz RD. Prenatal diagnosis and elective termination of Down syndrome in a racially mixed population in Hawaii, 1987-1996. Prenat Diagn 1999;19(2):136-41.
50. Natoli JL, Ackerman DL, McDermott S, et al. Prenatal diagnosis of Down syndrome: a systematic review of termination rates (1995-2011). Prenat Diagn 2012;32(2):142-53.
51. Shaffer BL, Caughey AB, Norton ME. Variation in the decision to terminate pregnancy in the setting of fetal aneuploidy. Prenat Diagn. 2006;26(8):667-71.
52. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 2010;27(1):1-7.
53. Wald NJ, Rodeck C, Hackshaw AK, et al. SURUSS in perspective. BJOG 2004;111(6):521-31.
54. Verweij EJ, Oepkes D, de Vries M, et al. Non-invasive prenatal screening for trisomy 21: what women want and are willing to pay. Patient Educ Couns 2013;93(3):641-5.
55. Morain S, Greene MF, Mello MM. A new era in noninvasive prenatal testing. N Engl J Med. 2013;369(6):499-501.
56. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370(9):799-808.
57. Song Y, Liu C, Qi H, et al. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn 2013;33(7):700-6.
58. Gil MM, Quezada MS, Bregant B, et al. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 2013;42(1):34-40.
59. Waitzman NJ, Romano PS, Grosse SD. Half-life of cost of illness estimates: the case of spina bifida. In Neural Tube Defects: From Origin to Treatment (1st edn), Wyszynski DF (ed.) USA: Oxford University Press, 2005; 342-51.